Join to View Full Profile
4500 San Pablo Rd SJacksonville, FL 32224
Phone+1 480-301-8000
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Hani Babiker, MD is a geriatrician in Jacksonville, Florida. He is currently licensed to practice medicine in Florida, Arizona, and New York.
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2012 - 2015
New York Presbyterian Hospital (Cornell Campus)Fellowship, Geriatric Medicine (Internal Medicine), 2008 - 2009
New York-Presbyterian/QueensResidency, Internal Medicine, 2006 - 2008
Comenius UniversityClass of 2000
Certifications & Licensure
FL State Medical License 2019 - 2026
AZ State Medical License 2009 - 2025
NY State Medical License 2008 - 2014
OH State Medical License 2008 - 2011
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years.Osama M Mosalem, Ahmed Abdelhakeem, Nayef H Abdel-Razeq, Hani Babiker
Expert Opinion on Investigational Drugs. 2025-03-01 - Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience.Paulina Marell, Ioannis Kournoutas, Jennifer Gile, Anina Peersen, Priyanshi Shah
The Oncologist. 2024-12-14 - 1 citationsBlood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.Reagan M Barnett, Albert Jang, Sree Lanka, PIngfu Fu, Leslie A Bucheit
Communications Medicine. 2024-12-02
Press Mentions
Improving Value in Pancreatic Cancer CareJanuary 4th, 2019
Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Patients with Central Nervous System Metastases from BRAF+ or MEK-Mutated Metastatic MelanomaNovember 26th, 2018
Immunotherapy—Cancer's New FrontierApril 5th, 2018- Join now to see all
